199 related articles for article (PubMed ID: 31646354)
1. Role of 18F-FDG PET/CT in restaging and follow-up of patients with GIST.
Albano D; Mattia B; Giubbini R; Bertagna F
Abdom Radiol (NY); 2020 Mar; 45(3):644-651. PubMed ID: 31646354
[TBL] [Abstract][Full Text] [Related]
2. Role of
Albano D; Zizioli V; Treglia G; Odicino F; Giubbini R; Bertagna F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):10-16. PubMed ID: 30396849
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Prognostic Value of
Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic
Albano D; Bonacina M; Savelli G; Ferro P; Busnardo E; Gianolli L; Camoni L; Giubbini R; Bertagna F
Jpn J Radiol; 2022 Jan; 40(1):66-74. PubMed ID: 34272721
[TBL] [Abstract][Full Text] [Related]
5. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis.
Kroese TE; Goense L; van Hillegersberg R; de Keizer B; Mook S; Ruurda JP; van Rossum PSN
Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29917073
[TBL] [Abstract][Full Text] [Related]
6. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Prognostic Role of 18F-FDG PET/CT in Pediatric Ewing Sarcoma.
Albano D; Dondi F; Schumacher RF; D'Ippolito C; Porta F; Giubbini R; Bertagna F
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e79-e86. PubMed ID: 31135716
[TBL] [Abstract][Full Text] [Related]
9. Clinical and prognostic value of
Albano D; Zizioli V; Odicino F; Giubbini R; Bertagna F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):87-93. PubMed ID: 30573388
[TBL] [Abstract][Full Text] [Related]
10. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
11. Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.
Rasheed R; Al-Kandari F; Ghanem M; Marafi F; Usmani S
Asian Pac J Cancer Prev; 2020 Feb; 21(2):511-515. PubMed ID: 32102532
[TBL] [Abstract][Full Text] [Related]
12. Performance of F-18 FDG PET/CT for predicting malignant potential of gastrointestinal stromal tumors: A systematic review and meta-analysis.
Kim SJ; Lee SW
J Gastroenterol Hepatol; 2018 Mar; 33(3):576-582. PubMed ID: 28994187
[TBL] [Abstract][Full Text] [Related]
13. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
[TBL] [Abstract][Full Text] [Related]
14. Role of
Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. Postoperative FDG-PET/CT staging in GIST: is there a benefit following R0 resection?
Hahn S; Bauer S; Heusner TA; Ebeling P; Hamami ME; Stahl A; Forsting M; Bockisch A; Antoch G
Eur J Radiol; 2011 Dec; 80(3):670-4. PubMed ID: 20970938
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
18. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
[TBL] [Abstract][Full Text] [Related]
19. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
[TBL] [Abstract][Full Text] [Related]
20. Metabolic behavior and prognostic role of pretreatment 18F-FDG PET/CT in gist.
Albano D; Bosio G; Tomasini D; Bonù M; Giubbini R; Bertagna F
Asia Pac J Clin Oncol; 2020 Oct; 16(5):e207-e215. PubMed ID: 32762133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
